title: Efficacy of Bicalutamide 150-mg Monotherapy Compared With Combined Androgen Blockade in Patients With Locally Advanced Prostate Cancer.
abstract: OBJECTIVE
  We compared the efficacy, survival rate, and adverse events between bicalutamide 150-mg monotherapy and combined androgen blockade (CAB) in men with locally advanced prostate cancer.
  
  
  METHODS
  From March 2003 to July 2012, we retrospectively included 74 patients who were treated for more than 3 months and were followed up for more than 6 months. 25 men were treated with bicalutamide 150-mg only (group 1) and 49 men received CAB (group 2). Serum prostate-specific antigen (PSA) change, survival rate, and adverse events were compared between the 2 groups.
  
  
  RESULTS
  The PSA levels before and after treatment were 37.0±32.8 ng/mL and 9.5±27.0 ng/mL in group 1 (p<0.001) and 50.2±40.0 ng/mL and 20.0±35.8 ng/mL in group 2 (p<0.001). Mean survival rates were 78.9% in group 1 and 52.3% in group 2 (p=0.055). There were no statistically significant differences in adverse events between the 2 groups (p=0.304). The International Index of Erectile Function 5 (IIEF-5) score before treatment was 19.3±5.9 in group 1 and 18.3±5.8 in group 2 (p=0.487). The IIEF-5 score after treatment was 17.1±6.3 in group 1 and 14.0±6.1 in group 2, which was a statistically significant difference (p=0.036).
  
  
  CONCLUSIONS
  The PSA change, mean survival rate, and adverse events in patients with locally advanced prostate cancer treated with bicalutamide 150-mg and CAB did not differ significantly. However, sexual function was better in the bicalutamide 150-mg group. Therefore, bicalutamide 150-mg monotherapy could be considered as a treatment for locally advanced prostate cancer in patients concerned about sexual function.
authors.affiliation: Department of Urology, Dongguk University College of Medicine, Gyeongju, Korea.
authors.forename: Yu Jin
authors.initials: YJ
authors.lastname: Kang
authors.affiliation: Department of Urology, Dongguk University College of Medicine, Gyeongju, Korea.
authors.forename: Ki Ho
authors.initials: KH
authors.lastname: Kim
authors.affiliation: Department of Urology, Dongguk University College of Medicine, Gyeongju, Korea.
authors.forename: Kyung Seop
authors.initials: KS
authors.lastname: Lee
keywords: Bicalutamide; Prostatic neoplasms; Therapy